Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 24468868)

1.

Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration.

Aguilar G, Azanza JR, Carbonell JA, Ferrando C, Badenes R, Parra MA, Sadaba B, Navarro D, Puig J, Miñana A, Garcia-Marquez C, Gencheva G, Gutierrez A, Marti FJ, Belda FJ.

J Antimicrob Chemother. 2014 Jun;69(6):1620-3. doi: 10.1093/jac/dkt542. Epub 2014 Jan 26.

2.

Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration.

Leitner JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Jäger W, Böhmdorfer M, Thalhammer F.

J Antimicrob Chemother. 2011 Apr;66(4):880-4. doi: 10.1093/jac/dkq545. Epub 2011 Jan 22.

3.

Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.

Maseda E, Grau S, Villagran MJ, Hernandez-Gancedo C, Lopez-Tofiño A, Roberts JA, Aguilar L, Luque S, Sevillano D, Gimenez MJ, Gilsanz F.

J Antimicrob Chemother. 2014 Jun;69(6):1624-32. doi: 10.1093/jac/dku013. Epub 2014 Feb 5.

4.

[Echinocandins in a critically ill patient during continuous venovenous renal replacement].

Aguilar G, Carbonell JA, Ferrando C, Badenes R, Belda FJ.

Rev Iberoam Micol. 2012 Apr-Jun;29(2):85-9. doi: 10.1016/j.riam.2012.03.005. Spanish.

PMID:
22463783
5.

Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis.

Liu P, Ruhnke M, Meersseman W, Paiva JA, Kantecki M, Damle B.

Antimicrob Agents Chemother. 2013 Apr;57(4):1672-6. doi: 10.1128/AAC.02139-12. Epub 2013 Jan 18.

6.

Low but sufficient anidulafungin exposure in critically ill patients.

van Wanrooy MJ, Rodgers MG, Uges DR, Arends JP, Zijlstra JG, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2014;58(1):304-8. doi: 10.1128/AAC.01607-13. Epub 2013 Oct 28.

7.

Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.

Mariat C, Venet C, Jehl F, Mwewa S, Lazarevic V, Diconne E, Fonsale N, Carricajo A, Guyomarc'h S, Vermesch R, Aubert G, Bidault R, Bertrand JC, Zeni F.

Crit Care. 2006 Feb;10(1):R26.

8.

Anidulafungin for the treatment of invasive candidiasis.

Mayr A, Aigner M, Lass-Flörl C.

Clin Microbiol Infect. 2011 Mar;17 Suppl 1:1-12. doi: 10.1111/j.1469-0691.2010.03448.x. Review.

PMID:
21251147
9.

[Echinocandins: searching for differences. The example of their use in patients requiring continuous renal replacement therapy].

de la Llama-Celis N, Huarte-Lacunza R, Gómez-Baraza C, Cañamares-Orbis I, Sebastián-Aldeanueva M, Arrieta-Navarro R.

Rev Esp Quimioter. 2012 Dec;25(4):240-4. Review. Spanish.

10.

Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration.

Fuhrmann V, Schenk P, Jaeger W, Miksits M, Kneidinger N, Warszawska J, Holzinger U, Kitzberger R, Thalhammer F.

J Antimicrob Chemother. 2007 Nov;60(5):1085-90. Epub 2007 Sep 13.

11.

Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.

Reboli AC, Rotstein C, Kett DH, Maschio M, Cartier S, Chambers R, Tarallo M.

Pharmacoeconomics. 2011 Aug;29(8):705-17. doi: 10.2165/11584810-000000000-00000.

PMID:
21591820
12.
13.

Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.

Cohen-Wolkowiez M, Benjamin DK Jr, Piper L, Cheifetz IM, Moran C, Liu P, Aram J, Kashuba AD, Capparelli E, Walsh TJ, Hope WW, Smith PB.

Clin Pharmacol Ther. 2011 May;89(5):702-7. doi: 10.1038/clpt.2011.26. Epub 2011 Mar 16.

14.

Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study.

Markou N, Fousteri M, Markantonis SL, Zidianakis B, Hroni D, Boutzouka E, Baltopoulos G.

J Antimicrob Chemother. 2012 Oct;67(10):2459-62. doi: 10.1093/jac/dks257. Epub 2012 Jul 12.

15.

Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis.

Dimopoulos G, Paiva JA, Meersseman W, Pachl J, Grigoras I, Sganga G, Montravers P, Auzinger G, Sá MB, Miller PJ, Marček T, Kantecki M, Ruhnke M.

Int J Antimicrob Agents. 2012 Dec;40(6):521-6. doi: 10.1016/j.ijantimicag.2012.07.018. Epub 2012 Sep 19.

16.

EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.

Zaragoza R, Ferrer R, Maseda E, Llinares P, Rodriguez A; EPICO Project Group.

Rev Iberoam Micol. 2014 Jul-Sep;31(3):157-75. doi: 10.1016/j.riam.2014.06.001. Epub 2014 Jun 21.

PMID:
25113990
17.
18.

Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration.

Fuhrmann V, Schenk P, Jaeger W, Ahmed S, Thalhammer F.

J Antimicrob Chemother. 2004 Oct;54(4):780-4. Epub 2004 Sep 3.

19.

Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration.

Malone ME, Corrigan OI, Kavanagh PV, Gowing C, Donnelly M, D'Arcy DM.

Int J Antimicrob Agents. 2013 Oct;42(4):335-42. doi: 10.1016/j.ijantimicag.2013.06.011. Epub 2013 Aug 4.

PMID:
23920093
20.

Echinocandin use in the neonatal intensive care unit.

Caudle KE, Inger AG, Butler DR, Rogers PD.

Ann Pharmacother. 2012 Jan;46(1):108-16. doi: 10.1345/aph.1Q346. Epub 2011 Dec 20. Review.

PMID:
22190252
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk